Celnovte achieved outstanding results in the 2024 NordiQC external quality assessment

2024-05-30

By celnovte

Share to:

Celnovte Biotech is proud to announce our outstanding results in the 2024 NordiQC external quality assessment. Our independently developed antibodies, ER (clone: C6H7), PR (clone: C4D10), and HER2 (clone: C1F7), all achieved exceptional staining results in the Run B37 test. When paired with Celnovte’s MicroStacker™ secondary antibody polymer detection system, the detection of ER and PR provides better results. This achievement underscores our commitment to high-quality, cost-effective antibody production and our technical excellence in immunohistochemistry. We will continue to deliver superior products and services to pathologists worldwide.

pr-c4d10

er-c6h7

her2-c1f7

About Celnovte Biotech:

Celnovte Biotech specializes in the research, development, manufacturing, and distribution of advanced pathological diagnostic reagents and instruments. Our market-leading portfolio includes IHC, CISH, and FISH products, designed to meet the highest standards of sensitivity and specificity.

(1) MicroStacker™ IHC Detection System: Renowned for its unsurpassed sensitivity and specificity.

(2) PolyStacker™ Technology: Reduces turnaround time of frozen section IHC experiments to as short as 10 minutes.

(3) SuperISH™ RNA In-Situ Hybridization Technology: Enables detection of RNA targets at the single molecular level and single-cell resolution.

(4) Innovative Automated Instrumentation: Including IHC slide stainers, H&E stainers, special stainers, cytopathology instruments, and digital slide scanners. Since 2018, we have successfully installed over 600 units of fully automated IHC stainers globally.

Stay Connected:

(1) Explore the latest in pathology innovations on our LinkedIn Page.

(2) Check out our brochures here.

(3) Follow our facebook for the news: Facebook Page.

None

🌟 Exciting Career Opportunity Alert! 🌟